United States Securities and Exchange Commission
                         Washington, D. C.  20549


                                FORM 10-QSB


[X]  QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES
     EXCHANGE ACT OF 1934

     For the quarterly period March 31, 2005

[ ]  TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT OF 1934

     For the transition period from                to
                                    --------------    ---------------

                       Commission File No. 000-32393
                       -----------------------------

                                eGene, Inc.
                                -----------
       (Exact Name of Small Business Issuer as Specified in its Charter)

          NEVADA                                        87-0645507
          ------                                        ----------
   (State or Other Jurisdiction of                 (I.R.S. Employer I.D. No.)
    incorporation or organization)

                   17841 Fitch, Irvine, California 92614
                   -------------------------------------
                 (Address of Principal Executive Offices)

                Issuer's Telephone Number:  (949) 250-8686

Check whether the Registrant (1) filed all reports required to be filed by
Section 13 or 15(d) of the Exchange Act during the past 12 months (or for such
shorter Period that the issuer was required to file such reports), and (2) has
been subject to such filing requirements for the past 90 days. Yes [X]  No [ ]

             APPLICABLE ONLY TO ISSUERS INVOLVED IN BANKRUPTCY
                PROCEEDINGS DURING THE PRECEDING FIVE YEARS

                              Not applicable.

Check whether the Registrant filed all documents and reports required to be
filed by Section 12, 13 or 15(d) of the Exchange Act after the distribution of
securities under a plan confirmed by a court.

     Yes       No
         ---     ---

                   APPLICABLE ONLY TO CORPORATE ISSUERS

Indicate the number of shares outstanding of each of the Registrant's classes
of common stock, as of the latest practicable date.

The number of our outstanding shares of common stock as of April 30, 2005, was
13,429,171 (actual); however, assuming all stockholders of BioCal Technology,
Inc., a California corporation ("BioCal"), who did not perfect dissenters'
rights in the merger of our wholly-owned subsidiary that was formed for the
sole purpose of merging with and into BioCal submit their BioCal shares for
exchange under that Agreement and Plan of Merger and by which BioCal became a
wholly-owned subsidiary of ours, then there will be 14,908,246 outstanding
shares.

Transitional Small Business Disclosure Format (Check One):  Yes  X   No
                                                                ---   ---



                             eGene,
                       Table of Contents
                                                                         Page

PART I    FINANCIAL INFORMATION

Item 1.   Financial Statements
          Condensed Consolidated Balance Sheet as of March 31, 2005

          Condensed Consolidated Statements of Operations for the
          Three Months Ended March 31, 2005 and 2004

          Condensed Consolidated Statements of Cash Flows for the
          Three Months Ended March 31, 2005 and 2004

          Notes to Unaudited Condensed Consolidated Financial Statements

Item 2.   Management's Discussion and Analysis of Financial Condition and
          Results of Operations

Item 3.   Controls and Procedures

PART II   OTHER INFORMATION

Item 1.   Legal Proceedings

Item 2.   Unregistered Sales of Equity Securities and Use of Proceeds

Item 3.   Defaults upon Senior Securities

Item 4.   Submission of Matters to a Vote of Security Holders

Item 5.   Other Information

Item 6.   Exhibits and Reports on Form 8-K

SIGNATURES
 EX-31.1 302 Certification of Udo Henseler
 EX-31.2 302 Certification of Jeffrey Williams
 EX-32   906 Certification

                      PART I - FINANCIAL INFORMATION

Item 1.   Financial Statements.

          The Financial Statements of the Registrant required to be filed with
this 10-QSB Quarterly Report were prepared by management, and commence on the
following page, together with Related Notes.  In the opinion of management,
the Financial Statements fairly present the financial condition of the
Registrant.

                 CONDENSED CONSOLIDATED BALANCE SHEET

                          (unaudited)


                                            31-Mar-05
     ASSETS
     Current Assets
          Cash                                $183,022
          Accounts Receivable                 $211,127
          Inventory                           $275,744
     Total Current Assets                     $669,893
     Fixed Assets
          Computer Equipment                  $ 39,239
          Equipment and Machinery             $ 42,858
          Furniture & Fixtures                $ 18,413
          Tooling                             $227,983
          Less Accumulated Depreciation      ($ 78,248)
     Total Fixed Assets                       $250,245
     Other Assets
          Deferred Patent Costs               $292,630
           Deposits                           $ 24,849
     Total Other Assets                       $317,479
TOTAL ASSETS                                $1,237,617
                                            ==========
LIABILITIES & STOCKHOLDERS' EQUITY
     Liabilities
          Current Liabilities
               Accounts Payable               $186,628
               Accrued Payroll                $180,920
               Accrued Vacation Pay           $ 33,897
               Warranty Accrual               $ 43,645
          Total Current Liabilities           $445,090
     Stockholders' Equity
          Common Stock                        $ 14,908
          Additional Paid in Capital        $4,712,173
          Deficit Accumulated during
            Development Stage              ($3,934,554)
     Total Stockholders' Equity               $792,527
TOTAL LIABILITIES & STOCKHOLDERS' EQUITY    $1,237,617
                                            ==========
<PAGE>
                 CONDENSED STATEMENTS OF OPERATION

                      (unaudited)
                                                                    From
                                    Three Months   Three Months   Inception
                                       Ended          Ended      3/1/1999 to
                                     3/31/2005      3/31/2004     3/31/2005
Revenues
     Sales                            $274,151       $141,844     $1,171,160
     Services                                -              -       $181,646
                                     ---------      ---------    -----------
Total Revenues                         274,151        141,844      1,352,806
                                     ---------      ---------    -----------
Cost of Goods Sold                     133,759         78,970        659,000
                                     ---------      ---------    -----------
Gross Profit                           140,392         62,874        693,806
                                     ---------      ---------    -----------
Expenses
     Accounting & Audit                 26,505          5,000         60,511
     Amortization  & Depreciation        6,295         11,331         85,111
     General Office Expenses             2,351          2,579         97,628
     Insurance                          18,932         10,334        114,198
     Legal Expenses                      4,191          6,679         14,803
     Manufacturing & Production          3,747          9,105      1,079,010
     Marketing & Sales                  23,526         15,664        225,067
     Office Equipment                    1,934          3,748         15,780
     Office Supplies                     4,097          5,368          4,097
     Postage and Delivery                2,909            977         11,180
     Professional Fees                  10,313              0        259,459
     Rent - Building                    14,568          6,000        120,486
     Research & Development             10,308        116,352         10,308
     Salaries, Wages & Taxes           271,715        202,313      2,422,411
     Telephone & Utilities               5,367          3,689         64,666
     Warranty Expense                                                 43,645
                                     ---------      ---------    -----------
Total Expenses                         406,758        399,139      4,628,360
                                     ---------      ---------    -----------
Net Loss Before Income Taxes          (266,366)      (336,265)    (3,934,554)
                                     ---------      ---------    -----------
Current Year Provision for Income Taxes      0              0              0
                                     ---------      ---------    -----------
Net Loss                              (266,366)      (336,265)    (3,934,554)
                                     =========      =========    ===========
Loss Per Share-Basic & Diluted          ($0.02)        ($0.04)             -
                                     =========      =========    ===========
Weighted Average Shares Outstanding 14,787,659      9,079,049              -
                                    ==========      =========
<PAGE>


            CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
                           (unaudited)

                                                                    From
                                    Three Months   Three Months   Inception
                                       Ended          Ended      3/1/1999 to
                                     3/31/2005      3/31/2004     3/31/2005
Cash Flows From Operating Activities
     Net Income (Loss)                (266,366)      (336,265)    (3,934,554)
     Adjustments of net income (loss)
     to net cash provided by operations:
          Amortization                     224            922          6,864
          Depreciation                   6,071         10,409         78,248
          Stock issued for services                                   48,790
          (Increase) decrease in current
          assets                        23,786          7,907       (486,871)
          Increase (decrease) in
          current liabilities           32,160        139,016        445,090
                                     ---------      ---------    -----------
     Net cash provided (used) by
     operating activities             (204,125)      (178,011)    (3,842,433)
                                     ---------      ---------    -----------

Cash Flows From Investing Activities
     Purchases of Fixed Assets               0         (4,502)      (328,493)
     (Increase) decrease in other
     assets                            (20,216)        (8,701)      (324,342)
                                     ---------      ---------    -----------
     Net cash provided (used) by
     investing activities              (20,216)       (13,203)      (652,835)
                                     ---------      ---------    -----------

Cash Flows from Financing
     Capital Stock Issued               10,583        256,001      4,678,290
                                     ---------      ---------    -----------

Net Increase (Decrease) in cash       (213,758)        64,787        183,022

Cash at beginning of period            396,780        275,192              0
                                     ---------      ---------    -----------
Cash at end of period                  183,022        339,979        183,022
                                     =========      =========    ===========

Supplemental disclosure of cash flow
information
     Interest paid                           0              0              0
     Income taxes paid                       0              0              0

                     See accompanying notes.
<PAGE>
                           eGene, Inc.
        NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
                        March 31, 2005

                         (Unaudited)


1. ORGANIZATION AND INTERIM FINANCIAL STATEMENTS

     Effective July 13, 2004, Centroid Consolidated Mines Co., (Centroid),
which changed its name to eGene, Inc. (eGene), completed a merger with BioCal
Technology, Inc., (BioCal) a private California corporation in the business of
developing, manufacturing, and marketing genetic analyzer systems and reagents
for the global genetic testing market. In conjunction with our merger, we
raised $1.6 million in private funding. We had no material business operations
at the time that we acquired BioCal Technology.

     The merger caused BioCal to become a wholly-owned subsidiary of eGene, a
dormant, publicly held Nevada corporation.  The terms of the merger provided
that eGene exchange one of its shares of common stock for every three
outstanding shares of common stock of BioCal and one of its options to acquire
shares of common stock of eGene for every three outstanding options to acquire
common stock of BioCal. The combination was a "reverse merge". The transaction
was accounted for as a recapitalization of BioCal wherein the net assets are
brought forward at their net book value with no goodwill recognized, and the
pre-merger financial statements of BioCal became the historical financial
statements of the combined company.

     The directors and executive officers of BioCal subsequently became the
directors and officers of the reorganized entity. Our Centroid Nevada
corporation has changed its name to eGene, Inc.

     The accompanying unaudited consolidated financial statements have been
prepared in accordance with generally accepted accounting principles for
interim financial information and with the instructions to Form 10-QSB and
Article 10 of Regulation S-X of the Securities and Exchange Commission
("SEC").  Accordingly, they do not include all of the information and
footnotes required by accounting principles generally accepted in the United
States for complete financial statements.   In the opinion of management, all
adjustments (consisting of normal recurring entries) considered necessary for
a fair presentation have been included.  Operating results for the three
months ended March  31, 2005, are not necessarily indicative of the
results that may be expected for the full year ending December 31, 2005.

Principles of Consolidation

     eGene's financial statements include the accounts of its wholly owned
subsidiary BioCal Technology, Inc. All significant inter-company balances and
transactions have been eliminated in consolidation.

2.  UNREGISTERED SALES OF EQUITY SECURITIES

     The following stock options were exercised in the first quarter of 2005.

Udo Henseler                 1/31/2005             103,333 shares
Rolf Kojima                  2/16/2005              11,667 shares
Ming S. Liu                  3/16/2005              96,667 shares

          * These securities were sold under Rule 506 of Regulation D of the
            Securities and Exchange Commission and Section 4(2) of the
            Securities Act of 1933, as amended.  All purchasers were either
            "accredited investors" or directors, officers or affiliates of our
            Company.

3. STOCK-BASED COMPENSATION

     eGene accounts for its stock options and equity awards under the
intrinsic value method in accordance with the provisions of Accounting
Principles Board Opinion No. 25, "Accounting for Stock Issued to Employees",
and related interpretations, and has elected to follow the "disclosure only"
alternative prescribed by Financial Accounting Standards Board's SFAS No. 123,
"Accounting for Stock-Based Compensation".  Accordingly, no compensation
expense is recognized in eGene's financial statements for stock options
granted to employees, which had an exercise price equal to the fair value of
the underlying common stock on date of grant.  eGene accounts for stock
options listed to non-employees in accordance with the provisions of SFAS No.
123 and EITF No. 96-18, "Accounting for Equity Instruments that are issued to
other than Employees for Acquiring or in Conjunction with selling Goods or
Services".

     The following table illustrates the effect on net loss and net loss per
share if eGene had applied the fair value recognition provisions of SFAS No.
123, as amended by SFAS No. 148, "Accounting for Stock-Based Compensation-
Transition and Disclsoure- and amendment of FASB Statement No. 123."  For
purposes of pro forma disclosures, the estimated fair value of the options is
amortized to expense over the vesting period of the options using the
straight-line allocation method.  eGene's pro forma information is as follows:

                                               Jan - Mar 2005   Jan - Mar 2004
        Net loss, as reported                   $(266,366)        $(336,265)
        Compensation cost under fair value-
         based accounting method, net of tax          253               658
        Net loss, pro forma                      (266,619)         (336,923)

        Net loss per common share
         Basis and Diluted
          As reported                              $(0.02)           $(0.04)
          Pro forma                                 (0.02)            (0.04)

        Weighted average shares                14,787,659         9,079,049

     The fair value under FAS 123 for options and equity awards granted were
estimated at the date of grant using a Black-Scholes option pricing model with
the following weighted average assumptions:

            Expected life (years)       5-8
            Interest rate                 3%
            Volatility                    0%
            Dividend yield                0%

4.  INVENTORIES

     Inventories are stated at the lower of cost or market.  Inventories at
March 31, 2005 consisted of the following:

                                                    March 31,
                                                      2005

           Finished goods                        $      80,000
           Work-in-process                              20,000
           Raw materials                               175,744
                                                 -------------
           Total                                 $     275,744
                                                 =============

Item 2. Management's Discussion and Analysis of Financial Condition and
Results of Operations.
----------------------

     This Management's Discussion and Analysis of Financial Condition and
Results of Operations as of March 31, 2005, and for the three month period
ended March 31, 2004, should be read in conjunction with our financial
statements included in our 10-KSB Annual Report for the year ended December
31, 2004, that was filed with the Securities and Exchange Commission on April
15, 2005(the "2004 10-KSB Annual Report").

     Statements made in this 10-QSB Quarterly Report which are not purely
historical are forward-looking statements with respect to our goals, plan
objectives, intentions, expectations, financial condition, results of
operations, future performance and business, including, without limitation,
(i) our ability to raise capital, and (ii) statements preceded by, followed by
or that include the words "may," "would," "could," "should," "expects,"
"projects," "anticipates," "believes," "estimates," "plans," "intends,"
"targets" or similar expressions.  Forward-looking statements involve inherent
risks and uncertainties, and important factors (many of which are beyond our
Company's control) that could cause actual results to differ materially from
those set forth in the forward-looking statements, including the following,
general economic or industry conditions, nationally and/or in the communities
in which we conduct business, changes in the interest rate environment,
legislation or regulatory requirements, conditions of the securities markets,
our ability to raise capital, changes in accounting principles, policies or
guidelines, financial or political instability, acts of war or terrorism,
other economic, competitive, governmental, regulatory and technical factors
affecting our operations, products, services and prices.

     Accordingly, results actually achieved may differ materially from
expected results in these statements.  Forward-looking statements speak only
as of the date they are made.  We do not undertake, and specifically
disclaims, any obligation to update any forward-looking statements to reflect
events or circumstances occurring after the date of such statements.

Executive Summary.
------------------

Business.
---------

     We are an emerging biotechnology company that utilizes our low cost core
technologies of capillary electrophoresis, microfluidics, advanced reagent,
liquid handling and automation to create leading edge and novel genetic
analyzer DNA fragment testing tools and RNA measurement solutions for the
biological/microbial materials and life sciences testing industries.  Our
objective is to provide new, effective and superior biological testing tools
and information for improved customer decision making and productivity.  We
deliver applications and tools to these industries that we believe will have
immediate commercial relevance.  Our HDA-GT12 (High-Performance DNA and RNA
Analyzer) system detects, quantifies, identifies and characterizes biological
organisms.  It advances and automates many routine and non-routine genetic
laboratory and industrial procedures such as are related, but not limited,  to
introduction of new and improved production methods and enhanced and novel
product development opportunities, quality control, security, genetic
identity, paternity, crime, bioterrorism, pathogen detection, drug monitoring,
safety methods and overall productivity.

    There are many applications critical to biological materials' management
for our technology platform, like market segments such as food, beverages,
environmental, sanitation, hygiene, pharmaceutical manufacturing, veterinary,
military bio-defense and research and development labs industries. We are,
however, currently addressing the relevant genetic testing applications in our
major target customer segments of University Research Laboratories,
Independent Research Institutes, Cancer Research and Public Health
Laboratories, Medical Schools, Research Hospitals, Pharmaceutical Companies
and Research Manufacturing and Biotechnology Companies. Once our products are
established with these customer groups we shall expand our reach into selected
high volume food sector applications and others.

     We believe that our products and technologies are uniquely capable of
addressing these markets.  Customers need superior information which will give
them unprecedented confidence in their decisions and in the quality of their
products regarding microbial and biological materials consequences. We believe
that we have addressed this urgent and increased customer need for a reliable,
accurate, high-throughput, low cost genetic tool for DNA Fragment
experimentation and testing and RNA analyses.

     We are developing three channels of distribution for our products:
direct to customers, indirect through our international network of
distributors, and through our, at this stage, early and developing original
equipment manufacturer ("OEM") channels.  Through these distributor channels,
we sell complete systems solutions, developed by us, to end customers.  Our
OEM distribution channel is only at its very early development stage, but
is an example, and is complementary to our distribution network activities as
it enables us to extend the commercial potential of our capillary microfluidic
genetic DNA HDA-GT12 system and advanced reagent and liquid handling
technologies into new industries and new applications with experienced
commercial partners. In the OEM channel, we plan to provide our enabling
technologies to potential commercial partners who then typically integrate the
application solution and market them to their end customers.

     By using direct, indirect distribution, and eventually OEM channels to
maximize penetration of our products and technologies into the marketplace,
we seek to position our Company as a leader in the low cost genetic tools
testing market.

     For additional information, please visit our web side at www.eGene.com.

Critical Accounting Policies, Estimates and Assumptions.
--------------------------------------------------------

     We consider our accounting policies related to revenue recognition,
inventory reserve, and warranty accrual to be critical accounting policies.
Inherent in our determination of when to recognize revenue, and in our
calculation of our inventory reserve and warranty accrual, are a number of
significant estimates, assumptions and judgments.  These estimates,
assumptions, and judgments include deciding whether the elements required to
recognize revenue from a particular arrangement are present and estimating the
amount of inventory obsolescence and warranty costs associated with shipped
products.  We base our estimates and judgments on historical experience and on
various other assumptions that we believe to be reasonable under the
circumstances.  Actual results could differ materially from these estimates.
There have been no material changes to our critical accounting policies since
we filed our 2004 Annual Report on Form 10-KSB with the Securities and
Exchange Commission. For a description of our critical accounting policies,
please refer to our 2004 Annual Report on Form 10-KSB.

First Quarter Overview.
-----------------------

     During the first quarter of 2005, we achieved several financial
milestones.  As reflected in our Consolidated Statements of Operations
contained in our Consolidated Financials Statements in Part I, Item 1 of this
Quarterly Report, our sales increased $132,000  or 93% from sales of
$142,000 in the first quarter of 2004.  This increase in our quarterly sales
reflects our continued early product sales ramp up from our acquisition of
BioCal in July of 2004.  We believe that the increase in sales boosts our
confidence to achieve more appreciable growth in the future.  We expect our
higher future sales to result in reduced operating losses and improved
operating cash flows.

     Our continuing goal is to attain sustainable revenue growth through
increased sales of our instruments to a more diversified and global customer
base and by increasing the percentage of our total sales that arises from
recurring sales sources such as consumable or aftermarket products.

     In addition to our goal of attaining more sustainable sales growth, we
are continuing to focus on improving our gross margins and controlling product
costs by seeking out the benefits of cost effective global low cost sourcing
in order to achieve operating cash flow break-even at lower overall sales.

     In conjunction with our merger in July 2004, we raised $1.6 million in
private funding.  We had no material business operations at the time that we
acquired BioCal

     Severe new equity funding delays are creating material commercial
success uncertainties for us.  Our accompanying financial statements have been
prepared assuming we will continue as a going concern.  However, as discussed
in Note 2 to our audited financial statements of our year ended December 31,
2004, that are contained in the 2004 10-KSB Annual Report, we have accumulated
losses and are still developing our planned principal operations.  These
factors and ongoing delays in new funding raise substantial doubt about our
ability to continue as a going concern.  Our financial statements do not
include any adjustments that might result from the outcome of this
uncertainty.

     We have limited financial resources and our operations from inception
through March 31, 2005, have been unprofitable.  We are still commencing our
planned principal operations and seeking increased capital funding.  If we
are unsuccessful in our efforts and cannot attain sufficient profitable
operations or if we cannot obtain additional sources of funding or
investments, we may substantially curtail or terminate our operations.

     During 2004 and the first three months of 2005, we enhanced our product
position with introductions of new product applications and two new Gel
Cartridges (4 and 8 channels) with integrated gel-chemistries designed to
handle different samples capacities with high detection sensitivity and
reproducibility to enhance user productivity.

     Over the next several quarters, we intend to introduce new high value
application targets.  While we are unable to project future sales from these
new introduction, we believe that the expanded ability to perform new and
high confidence analyses, will greatly enhance our positioning by allowing
customers to conduct genetic analyses that were previously not well or not at
all accomplished with the traditional testing technology platforms.

     We also continue to aggressively pursue our genetic microfluidics
adoption strategy and promote our enhanced product position to our expanding
customer base.  Examples of these activities were/are our distributor and
customer training tutorials during which we present our newest solutions to
existing and prospective customers.  A number of these programs have generated
new sales and leads that we believe will result in incremental product sales
for the second half of 2005.

Results of Operations.
----------------------

Revenue.
--------

     Total sales increased for the three months ended March 31, 2005, as
compared to the same period in 2004.  Our sales increased 132,000 or 93% from
sales of $142,000 in the first quarter of 2004.  This increase in our
quarterly sales reflects our continued early product sales ramp up from our
acquisition of the young private BioCal company in July of 2004.  The
increases in sales boost our confidence to achieve more appreciable growth in
the future.  We expect our higher future sales to result in reduced operating
losses and improved operating cash flows.  We had no material business
operations at the time that we acquired BioCal.

                   Three Months Ended
                     March 31,
                    2005      2004      $change   %change 2004

Total Revenues     $274,151  $141,844   $132,307       93%

Cost of Sales.
--------------

     In addition to our goal of attaining more sustainable revenue growth, we
are continuing to focus on improving our gross margins and controlling product
costs by seeking out the benefits of cost effective global low costs sourcing
opportunities in order to achieve operating cash flow break-even at lower
overall revenues.

Expenses.
----------

     Total expenses for the quarter ended March 31, 2005, were $407,000 and
$7,600 higher as compared to the same periods in 2004.

     The major expenses levels and increases were for payroll and research and
development materials.  The level of ongoing research and development expense
is highly dependent upon the number and significance of ongoing projects at
any particular time.  We currently expect research and development expenses to
continue to increase in future periods as we develop new product solutions and
enhancements.  Although we expect research and development spending to
increase, but only expanding in subsequent years based upon customer demand,
market conditions and our commercial growth.

     We expect to devote additional expense resources to continue our
research and development efforts activities, substantially strengthen and
broaden our marketing and sales infrastructure and for other general corporate
activities.

     Selling and marketing expenses are expected to increase primarily due to
planned increased sales calling for increases in personnel costs related to
our initial and future growth related construction of our marketing, sales and
service functions, and general increases in other marketing and sales support
initiatives.  We expect selling, marketing and product promotion expenses to
grow over the next several years to support our more global commercialization
of our products.

     General and administrative expenses are expected to increase as a result
of increased commercial activities and as a consequence of operating as a
public company subject to the many regularity demands.  Certain general and
administrative expenses in the legal and insurance categories increased
primarily due our BioCal merger and related consequences.  We anticipates that
general and administrative expenses will continue to increase but at a lesser
percentage rate of sales.

     The net loss for the quarter ended March 31, 2005, was $266,000 and
$70,000 lower, compared to the previous year quarterly loss of $336,265

Liquidity and Capital Resources.
--------------------------------

     Our cash and cash equivalents were $183,000 at March 31, 2005,
compared to $340,000 at of March 31, 2004.

     We have financed our operations from inception primarily through equity
sales and initial product sales and services.  The inclusion of BioCal
results of operations after July 14, 2004, had a significant impact on our
business and the comparability of cash flows on a period-over-period basis.

Cash Flows.
-----------

                                   Three Months Ended
                                         March 31,
                                     2005       2004        $change

Net Cash provided (used)
by operating activities       $(204,125)     $(178,011)    $ (26,114)

Cash Flows from
investing activities          $ (20,216)     $ (13,203)    $  (7,013)

Cash Flows from
Financing activities            $10,583      $ 256,001     $(245,418)

Operating Activities.
---------------------

     During the three months ended March 31, 2005, we used $204,000 of cash
for operating activities as compared to $178,000 of cash used in the same
period of 2004.  Current assets - receivables, inventory and other current
assets nominally offset by increases in current liabilities used cash of
$56,000, and operations used $260,000 during the three months ended March 31,
2005.  The increased use of cash for accounts receivable was due to increases
of our product sales base.  The increase in use of cash for inventories during
the three months ended March 31, 2005, is primarily related to an increase in
inventory levels related to expected increases in future product sales. In
2004, including our acquisition of BioCal, we had low inventories as product
sales were not significant.

Investing Activities.
---------------------

     Investing activities during the three months ended March 31, 2005,
were $20,000 for additional costs incurred for deferred patent legal fees.

Financing Activities.
---------------------

     During the three months ended March 31, 2005, expected new funding
activities from the sale of our common stock and options in various private
placements did not materialize.

     The material new equity funding delays are creating severe commercial
success uncertainties for us.  Our accompanying financial statements have been
prepared assuming we will continue as a going concern.  As discussed in Note 2
to our audited financial statements of our year ended 2004 that are contained
in our 2004 10-KSB Annual Report. we have accumulated losses and are still
developing our planned principal operations.  These factors and ongoing delays
in new funding raise substantial doubt about our ability to continue as a
going concern.  Our financial statements do not include any adjustments that
might result from the outcome of this uncertainty.

     We have limited financial resources and our operations through March 31,
2005, have been unprofitable.  We are still commencing our planned principal
operations and seeking increased capital funding.  If we are unsuccessful in
our efforts and cannot attain sufficient profitable operations or if we cannot
obtain additional sources of funding or investments, we may substantially
curtail or terminate our operations.

          If, however, our current in process private placement of "restricted
securities" to "accredited investors" only is successful and we achieve the
revenues to be derived from our commercial sales from our genetic products,
our cash balances will be sufficient to fund our operations at least through
2005. If we are unsuccessful in our efforts to obtain additional sources of
funding or investments, we may substantially curtail or terminate our
operations.

     Our future capital requirements will depend on many factors, including,
among others:

     * continued market acceptance of our genotyping products;

     * continued scientific progress in product development programs;

     * the magnitude and scope of our research and product development
       programs;

     * our  ability to maintain and establish additional, partnerships and
       licensing arrangements;

     * the time and costs involved in expanding and maintaining our
       manufacturing facilities;

     * the costs involved in preparing, filing, prosecuting, maintaining,
       defending and enforcing patent claims;

     * the potential need to develop, acquire or license new technologies and
       products; and

     * other factors not within our control.

    Our actual cash needs could vary considerably depending upon how
unsuccessful we are in our efforts to obtain additional sources of funding or
investments, opportunities and commercial uncertainties that may arise over
the course of the remaining period of 2005 and the full year 2006.  During or
after this period, if cash generated by operations is insufficient to satisfy
our liquidity requirements, we may need to sell additional equity or debt
securities or obtain additional credit arrangements.  An inability to obtain
additional financing may force delays in research and product development
activities and, ultimately, cause us to cease operations.

     In the future, we may seek additional funds to support our strategic
business needs and may seek to raise such additional funds through private or
public sales of securities, strategic relationships, bank debt, lease
financing arrangements or other available means.  If additional funds are
raised through the issuance of equity or equity-related securities,
stockholders may experience additional dilution, or such equity securities may
have rights, preferences or privileges senior to those of the holders of our
common stock.  If adequate funds are not available or are not available on
acceptable terms to meet our business needs, our business may be harmed.

Going Concern Qualification of our Auditors.
--------------------------------------------

     Our accompanying financial statements have been prepared assuming we
will continue as a going concern.  We have accumulated losses and are still
developing our planned principal operations.  These factors raise substantial
doubt about our ability to continue as a going concern.  Management's plans in
regard to these matters are also described in Note 2 of our audited financial
statements that are contained in our 2004 10-KSB Annual Report.  These
financial statements do not include any adjustments that might result from the
outcome of this uncertainty.

Risk Factors Affecting Operating Results.
-----------------------------------------

     The following risk factors should be considered, among others, in
evaluating eGene's business, products and prospects.  This list is not
inclusive.

Risks Related to Our Business.
------------------------------

Our Genetic Analyzer Products May Not Achieve Market Acceptance, Which Could
Cause Revenue to Grow Slowly or Decline.
----------------------------------------

     Our genetic analyzer products, which we developed, are still in
relatively early stages of their technology life cycle and have only recently
begun to be used commercially.  If these systems do not gain further market
acceptance, eGene will be unable to generate significant sales of these
products and our revenue may grow more slowly than expected or decline.  The
commercial success of our genetic analyzer products will depend upon capital
spending by our potential customers, and market acceptance of the merits of
our genetic analyzer capillary electrophoresis systems by biotechnology
companies, academic research centers and other companies that rely upon
genotyping analyses.  Market acceptance will depend on many factors,
including:

     * ability to demonstrate the advantages and potential economic value of
our genetic systems over alternative well-established technologies;

     * capital spending by our customers and potential customers, which has
been sluggish as a result of current economic conditions and other industry-
specific factors; and

     * ability to market our genetic analyzer  systems.

     Because the genotyping capillary electrophoresis systems have been in
operation for only a limited period of time, their accuracy, reliability, ease
of use and commercial value have not been fully established.  If the early
customers do not endorse our genotyping systems because these systems fail to
generate the quantities and quality of data they expect, are too difficult or
costly to use or are otherwise deficient, market acceptance would suffer and
further sales may be limited.  We cannot assure you that these customers'
efforts to put our high throughput systems into use will continue or will be
expeditious or effective.  Potential customers for these systems may also wait
for indications from eGene's early genetic system customers that our system
works effectively and generate substantial benefits.  Further, non-acceptance
by the market of our initial systems could undermine not only those systems
but subsequent systems as well.

     The genetic analyzer  productivity tools equipment market is competitive
and is characterized by technological change and frequent new product
introductions. The commercial success of our genetic systems depends upon
continued and expanding market acceptance of our systems and products by
biotechnology companies and genomics research organizations, and upon
availability to address quickly any performance problems that our customers
encounter.  We anticipate that our competitors will introduce new, enhanced
products in this market.  Our future success will depend on our ability to
offer new products and technologies that researchers believe are an attractive
alternative to current products and technologies that address the evolving
needs of our customers and that are technologically superior to new products
that may be offered by competitors.  We may experience difficulties or delays
in the development efforts for new products, and we may not ultimately be
successful in developing them.  Any significant delay in releasing new
products in this market could adversely affect us or our reputation, give a
competitor a first-to-market advantage or cause a competitor to achieve
greater market share.

     We intend to continue developing new, lower cost versions of our
genetic analyzer  systems with enhanced features that address existing or
emerging customer needs, such as novel assay functionalities.  If we are
unable to do so, our systems may not become more widely used and we may
experience a decline in revenue or slow revenue growth and may not achieve or
maintain profitability.

     Our Sales Cycle Can Be Lengthy, Which Can Cause Variability and
Unpredictability In Our operating Results.
------------------------------------------

     The sales cycles for our products, particularly in the genetic/life
sciences market, can be lengthy, which makes it more difficult for us to
forecast revenues in a given period, and may cause revenues and operating
results to vary significantly from period to period. Sales of our product to
the life sciences market often involves purchasing decisions by large public
and private institutions, and any purchases can require many levels of pre-
approval. In addition, many of these sales depend on these institutions
receiving research grants from various federal agencies, which grants vary
considerably from year to year in both in amount and timing due to the
political process. As a result, we may expend considerable resources on
unsuccessful sales efforts or we may not be able to complete transactions on
the schedule anticipated.

     eGene's Business May Be Adversely Affected By Downturns In The Economy.
     -----------------------------------------------------------------------

     We are subject to the capital spending patterns of this industry, which
over the past several years have been unfavorably impacted by general economic
conditions and increased competition.  If our customers and potential
customers do not increase their capital spending budgets, eGene could face
weak demand for our products.

     eGene's Industry Is Very Competitive.
     -------------------------------------

     Our business is highly competitive and our growth is dependent upon
market growth and our ability to enhance our existing products and introduce
new products on a timely basis.  One of the ways we may address the need to
develop new products is through acquisitions of complementary businesses and
technologies.  Acquisitions involve numerous risks.

     eGene Has Not Recorded Profitable Operations Since Its Inception And May
Never Achieve Profitably.
-------------------------

     We expect to incur future operating losses and may not achieve
profitably.  We have experienced development stage operating losses each year
since our inception and expect to incur additional operating losses for the
calendar year of 2005, primarily as a result of a current slow economic
climate, and expected continuing expenses for manufacturing capabilities,
research and product development costs and general and administrative costs.
We may never achieve profitability.

     Our operating results may fluctuate significantly and any failure to meet
financial expectations may disappoint securities analysts or investors and
result in a decline in its stock price.

     eGene Has Limited Manufacturing Experience.
     -------------------------------------------

     We have limited experience in manufacturing of our products and may
encounter manufacturing problems or delays, which could result in lost
revenue.

     eGene Depends On Its Key Personnel, The Loss Of Whom Would Impair Its
Ability to Compete.
-------------------

     We are highly dependent on the principal members of our management (CEO
Dr. Udo Henseler, Dr. Ming Liu and Varouj Amirkhanian - world-class
scientists).  The loss of services of any of these persons could seriously
harm product development, commercialization efforts and business success.  In
addition, research, product development and commercialization will require
additional skilled personnel in areas such as chemistry and biology, software
engineering and electronic engineering. Competition for and retention of
personnel, particularly for employees with technical expertise, is intense and
the turnover rate for these people is high.  If we are unable to hire, train
and retain a sufficient number of qualified employees, our ability to conduct
and expand our business could be reduced.  The inability to retain and hire
qualified personnel could also hinder the planned expansion of our business.

     eGene's Intellectual Property Rights May Not Protect It And Its Products.
     -------------------------------------------------------------------------

     Our products could infringe on the intellectual property rights of
others, which may cause us to engage in costly litigation and, if we are not
successful, could also cause us to pay substantial damages and prohibit us
from selling our products.  Third parties may assert infringement or other
intellectual property claims against us.  Even if these claims are without
merit, defending a lawsuit takes significant time, may be expensive and may
divert management attention from other business concerns.  We are not aware
of any third-party patents claims against us.

     We may need to initiate lawsuits to protect or enforce our patents,
which would be expensive and, if we lose, may cause us to lose some of our
intellectual property rights, which would reduce our ability to compete in the
market.  We rely on patents to protect our intellectual property and our
competitive position, especially in our capillary electrophoresis
microfluidics business.  The rights eGene relies upon to protect our
intellectual property underlying company products may not be adequate, which
could enable third parties to use this technology and would reduce our ability
to compete in the market.

     In addition to patents, we rely on a combination of trade secrets,
copyright and trademark laws, nondisclosure agreements and other contractual
provisions and technical measures to protect our intellectual property rights.
Nevertheless, these measures may not be adequate to safeguard the technology
underlying company products.

     Notwithstanding our efforts to protect our intellectual property, our
competitors may independently develop similar or alternative technologies or
products that are equal or superior to company technology and products without
infringing on any of our intellectual property rights or design around company
proprietary technologies.

     The Loss of One or More Suppliers of eGene May Have an Adverse Effect on
its Operations.
---------------

     We obtain some of the components and subassemblies included in our
systems from a single source or a limited group of suppliers, and the partial
or complete loss of one of these suppliers could cause production delays and a
substantial loss of revenue.

     We maintain only a limited number of long-term supply agreements with
its suppliers.

     Our reliance on a limited group of suppliers involves several risks,
including the following:

     * we may be unable to obtain an adequate supply of required components;

     * we have reduced control over pricing and the timely delivery of
components and subassemblies; and

     * company suppliers may be unable to develop technologically advanced
products to support our growth and development of new systems.

     Because the manufacturing of certain of these components and
subassemblies involves complex processes and requires long lead times, we
may experience delays or shortages caused by suppliers.  We believe that
alternative sources could be obtained at the same prices and on substantially
the same terms and conditions, if necessary, for most sole and limited source
parts.  However, if we were forced to seek alternative sources of supply or to
manufacture such components or subassemblies internally, we might be forced to
redesign company systems, which could prevent us from shipping our systems to
customers on a timely basis.

     eGene May Need Additional Capital.
     ----------------------------------

     Failure to raise additional capital or generate the significant capital
necessary to expand our operations and invest in new products could reduce
our ability to compete and result in lower revenue.  We anticipate that
our existing capital resources and in progress private placement will enable
us to maintain currently planned operations at least through the early year
2005.  However, we premise this expectation on our current successful private
placement which is lagging significantly in terms of cash in-flow so far. We
may need additional funding sooner than anticipated.  Our inability to raise
needed capital would harm our business. In addition, we may choose to raise
additional capital due to market conditions or strategic considerations even
if we believe we have sufficient funds for our current operating plans.  To
the extent that additional capital is raised through the sale of equity or
convertible debt securities, the issuance of these securities could result in
dilution to our stockholders.

     We currently have no credit facility or committed sources of capital.
To the extent operating and capital resources are insufficient to meet future
requirements, we will have to raise additional funds to continue the
development and commercialization of our technologies.  These funds may not be
available on favorable terms, or at all.  If adequate funds are not available
on attractive terms, we may be required to curtail operations significantly or
to obtain funds by entering into financing, supply or collaboration agreements
on unattractive terms

Risks Related to Owning Our Common Stock
----------------------------------------

     Our shares of common stock are traded on the OTC Bulletin Board under the
symbol "EGEI"; however, there is not and has not been any "established
trading market" for these securities.  Our stock price has very little
history, and you could lose a substantial portion of your investment.

     Our stock has been trading on the OTCBB only since October 2004.
We initially offered our common stock to the public at $1.00 per share in a
private placement to "accredited investors" only.  We expect that our stock
price will remain volatile as a result of a number of factors, including:

  *      announcements by our competitors of complementary or competing
         products and technologies;

  *      announcements of our financial results, particularly if they
         differ from investors' expectations; and

  *      general market volatility for technology stocks.

     These factors and fluctuations, as well as general economic, political
and market conditions, may materially adversely affect the market price of our
common stock.

     We are at risk of future securities class action litigation.

     Given the newness of our stock, we are at risk of having securities class
action lawsuits filed against us and our officers and directors. Such
securities litigation could result in potential liability, cause us to incur
litigation costs and divert management's attention and resources, any of which
could harm our business. In addition, announcements of lawsuits of this or
some other nature, and announcements of events occurring during the course of
the lawsuits, could cause our stock fall.

Quantitative and Qualitative Disclosures About Market Risk.
-----------------------------------------------------------

Interest Rate Sensitivity.
--------------------------

     Our primary investment objective is to preserve principal while at the
same time maximizing yields without significantly increasing risk. Our
portfolio includes money markets funds.

Item 3. Controls and Procedures.
--------------------------------

     We have evaluated our "disclosure controls and procedures" and our
"internal controls and procedures for financial reporting" as of March 31,
2005.  This evaluation was done under the supervision and with the
participation of management, including our chief executive officer and our
principal financial officer.

Evaluation of Disclosure Controls and Procedures.
-------------------------------------------------

     Regulations under the Securities Exchange Act of 1934 require public
companies, including our company, to evaluate any change in our "internal
control over financial reporting," which is defined as a process to provide
reasonable assurance regarding the reliability of financial reporting and
preparation of financial statements for external purposes in accordance with
accounting principles generally accepted in the United States. In connection
with our evaluation of our disclosure controls and procedures as of the end of
the period covered by this report, our Chief Executive Officer, Chief
Financial Officer, Executive VPs and Business Manager did not identify any
change in our internal control over financial reporting during the three
months ended March 30, 2005 that materially affected, or is reasonably likely
to materially affect, our internal control over financial reporting.
Disclosure controls are designed with the objective of ensuring that
information is accumulated and communicated to our management, including the
chief executive officer and principal financial officer, as appropriate to
allow timely decisions regarding required disclosure.  It should be noted
though that eGene is a young and emerging biotechnology company with limited
resources, funding and personnel, and that our evaluation of controls and
procedures were conducted in good faith considering the economic environment
of the company.


Changes in Internal Controls.
-----------------------------

     Internal controls over financial reporting are procedures which are
designed with the objective of providing reasonable assurance that: (1) our
transactions are properly authorized; (2) our assets are safeguarded against
unauthorized or improper use; and (3) our transactions are properly recorded
and reported, all to permit the preparation of our financial statements in
conformity with accounting principles generally accepted in the United States.
Among other matters, we evaluated our internal controls over financial
reporting to determine whether there were any "significant deficiencies" or
"material weaknesses," and sought to determine whether we have identified any
acts of fraud involving personnel who have a significant role in eGene's
internal controls. In the professional auditing literature, "significant
deficiencies" may be interpreted as being comparable as "reportable
conditions"; these are control issues that could have a significant adverse
effect on the ability to record, process, summarize, and report financial data
in the financial statements.  A "material weakness" is defined in the auditing
literature as a particularly serious reportable condition where the internal
control does not reduce to a relatively low level the risk that misstatements
caused by error or fraud may occur in amounts that would be material in
relation to the financial statements and would not be detected within a timely
period by employees in the normal course of performing their assigned
functions.

     There were no material changes in our internal controls over financial
reporting during the quarter ended March  31, 2005, that have materially
affected, or are reasonably likely to materially affect, our internal control
over financial reporting.

     Consistent with Section 10A(i)(2) of the Securities Exchange Act of 1934,
as added by Section 202 of the Sarbanes-Oxley Act of 2003, we are responsible
for listing the non-audit services approved by our Chief Executive Officer to
be performed by Mantyla McReynolds LLC, our independent auditor.  Non-audit
services are defined as services other than those provided in connection with
an audit or a review of our financial statements.

Limitations on the Effectiveness of Controls.
---------------------------------------------

     Our management, including our chief executive and principal financial
officer, does not expect that our disclosure controls or our internal controls
will prevent all error and all fraud.  A control system can provide only
reasonable, not absolute, assurance that the objectives of the control system
are met. Further, the design of a control system must reflect the fact that
there are resource constraints, and the benefits of controls must be
considered relative to their costs.  Because of the inherent limitations in
all control systems, no evaluation of controls can provide absolute assurance
that all control issues and instances of fraud, if any, within our Company
have been detected.  These inherent limitations include the realities that
judgments in decision-making can be faulty, and that breakdowns can occur
because of simple error or mistake.  Additionally, controls can be
circumvented by the individual acts of some persons, by collusion of two or
more people or by management override of the control.  Because of the inherent
limitations in a cost-effective control system, misstatements due to error or
fraud may occur and not be detected.

                   Part II   Other Information

Item 1. Legal Proceedings.
--------------------------

     None; not applicable.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.
--------------------------------------------------------------------

     The following stock options were exercised in the first quarter of 2005.

Udo Henseler                    1/31/2005           103,333 shares
Rolf Kojima                     2/16/2005            11,667 shares
Ming S. Liu                     3/16/2005            96,667 shares

          * These securities were sold under Rule 506 of Regulation D of the
            Securities and Exchange Commission and Section 4(2) of the
            Securities Act of 1933, as amended.  All purchasers were either
            "accredited investors" or directors, officers or affiliates of our
            Company.

Item 3. Defaults Upon Senior Securities.
----------------------------------------

     None; not applicable.

Item 4. Submission of Matters to a Vote of Security Holders.
------------------------------------------------------------

     None; not applicable.

Item 5. Other Information.
--------------------------

     None

Item 6.   Exhibits.
-------------------

Exhibits:

     31.1 302 Certification of Udo Henseler

     31.2 302 Certification of Jeffrey Williams

     32   906 Certification

                          SIGNATURES


     Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this Quarterly Report to be signed on its behalf by
the undersigned, thereunto duly authorized.

                                   eGene, Inc.



Dated: May 11, 2005          By:  /s/ Udo Henseler
                                   Udo Henseler
                                   Chairman of the Board and Chief
                                   Executive Officer


Dated: May 11, 2005           By:  /s/ Jeffrey Williams
                                   Jeffrey Williams
                                   Chief Financial Officer




<PAGE>